TLR5 antibody - N-terminal region (ARP31753_P050)
- Known as:
- TLR5 (anti-) - N-terminal region (ARP31753_P050)
- Catalog number:
- arp31753_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- TLR5 antibody - N-terminal region (ARP31753_P050)
Related genes to: TLR5 antibody - N-terminal region (ARP31753_P050)
- Gene:
- TLR5 NIH gene
- Name:
- toll like receptor 5
- Previous symbol:
- SLEB1
- Synonyms:
- TIL3, FLJ10052, MGC126430, MGC126431
- Chromosome:
- 1q41
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-25
- Date modifiied:
- 2016-10-05
Related products to: TLR5 antibody - N-terminal region (ARP31753_P050)
Related articles to: TLR5 antibody - N-terminal region (ARP31753_P050)
- To investigate the association of Toll-like receptor 5 (TLR5) gene polymorphisms with the clinical efficacy of ustekinumab (UST) in the treatment of Crohn's disease (CD) patients. The patients with active CD who received UST treatment were retrospectively recruited from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University between January 2022 and April 2025. The loci rs5744168 and rs5744174 in TLR5 gene were genotyped by multiplex polymerase chain reaction-ligase detection reaction technique. The clinical response of CD patients was evaluated by Harvey-Bradshaw index (HBI) at week 8 of follow-up. The patients were divided into the response group (a decline of HBI≥ 3 points compared with week 0) and the non-response group. The mucosal healing was assessed by the Simplified Endoscopic Score for Crohn's disease (SES-CD) at week 32 of UST treatment. The patients were divided into the mucosal healing group (SES-CD≤2 points or absence of mucosal ulcerations) and the mucosal non-healing group. The distribution differences of TLR5 gene polymorphism were compared between the response group and the non-response group, as well as between the mucosal healing group and the mucosal non-healing group. The genotypes or alleles with distribution differences were included into unconditional logistic regression models to investigate the association between the gene polymorphisms of TLR5 and the clinical efficacy of UST treatment in CD patients. A total of 198 CD patients were included (133 males, 65 females), with age of (32±12) years. There were 117 cases in the response group and 81 cases in the non-response group at week 8 of UST treatment. The homozygous variant genotype (GG) [1.7% (2/117) vs 11.1% (9/81), corrected =0.024] and variant allele (G) [15.8% (37/234) vs 27.8% (45/162), corrected =0.008] of locus rs5744174 in the response group were less frequent than those in the non-response group. The homozygous variant genotype (GG) (=0.17, 95%: 0.04-0.83, =0.029) and variant allele (G) (=0.51, 95%: 0.31-0.85, =0.010) of locus rs5744174 were shown to be associated with the clinical response at week 8. There were 79 cases in the mucosal healing group and 119 cases in the mucosal non-healing group at week 32 of UST treatment. The frequency of variant genotype (GA+AA) [15.2% (12/79) vs 1.7% (2/119), corrected <0.001] and the frequency of variant allele (A) [9.5% (15/158) vs 0.8% (2/238), corrected <0.001] of locus rs5744168 in mucosal healing group were higher than those in the mucosal non-healing group. The variant genotype (GA+AA) (=8.94, 95%: 1.88-42.50, =0.006) and variant allele (A) (=9.54, 95%: 2.09-43.66, =0.004) of locus rs5744168 were found to be related with the mucosal healing at week 32. Among the patients with active CD receiving UST treatment, the variation of locus rs5744174 in TLR5 gene may be associated with a reduced clinical response rate at week 8. However, the variation of locus rs5744168 may be linked to an increased mucosal healing rate at week 32. - Source: PubMed
Lu J HShao X XLin D PXu YMa G LJiang Y - This study evaluated the immunomodulatory effects of dietary β-glucan derived from the marine diatom Chaetoceros muelleri on immune responses and survival of Nile tilapia (Oreochromis niloticus) following Tilapia Lake Virus (TiLV) infection. Juvenile tilapias were fed diets supplemented with 0.1% or 0.2% β-glucan for 14 days prior to viral challenge. Fish were subsequently challenged with TiLV and immune-related gene expression was analysed in spleen and liver tissues. Fish fed the 0.1% β-glucan diet showed significantly lower cumulative mortality (26.67%) compared with the control group (55.56%) and the 0.2% group (42.22%). Dietary β-glucan significantly influenced the expression of multiple immune-related genes including cytolytic (NCCRP-1), stress-related gene (Hsp70), antimicrobial protein (C-lysozyme), cytokine (IL-8), pattern recognition receptors (TLR3, TLR5, TLR9), signalling adaptor (myD88), antiviral effector (Mx, RSAD-2), adaptive immunity (IgM, CD4). Correlation heatmap and gene co-expression network analyses revealed coordinated immune regulation, with Mx, RSAD-2 and CD4 acting as central hub genes associated with antiviral defence pathways. These results demonstrate that moderate dietary supplementation with C. muelleri-derived β-glucan enhances immune responses and improves resistance to TiLV infection in Nile tilapia, supporting its potential application as a functional feed additive in tilapia aquaculture. - Source: PubMed
Publication date: 2026/04/13
Madyod SulaimanPholmai SuwannaPrombanchong ThitikornLaksana-Aut PatcharaponUnajak SasimanasHirono IkuoWuthisuthimethavee Suwit - Flagellin, the key structural protein of bacterial flagella, is known to stimulate Toll-like receptor 5 (TLR5) signaling, making it an effective adjuvant for nasal, intramuscular, or subcutaneous routes of vaccination. Here, we investigate the potential of intradermal flagellin delivery to enhance adaptive immunity in mouse and pig models. Our study shows that intradermal administration of flagellin enhances systemic antibody responses to co-administered antigens in a TLR5-dependent manner. Transcriptional analysis of mouse and pig skin revealed that flagellin induces an early pro-inflammatory response associated with pathways essential for adjuvant activity, such as dendritic cell maturation or communication between innate and adaptive immune cells. This immune activation is swiftly detected in the bloodstream of vaccinated animals. Furthermore, our investigation reveals flagellin's capacity to activate innate immunity of structural skin cells including human keratinocytes and fibroblasts. Collectively, our findings underscore flagellin' potential to improve the efficacy of intradermal vaccine formulations by engaging skin structural cells, thus advancing the landscape of vaccination strategies. - Source: PubMed
Publication date: 2026/04/04
Sirard Jean-ClaudeCayet DelphineFougeron DelphineSoulard DaphnéeTabareau JulienHot DavidBarnier-Quer ChristopheJakob VirginieCollin NicolasMollenkopf Hans-JoachimStockhofe-Zurwieden NorbertVan Maele Laurye - The WHO has classified as a category 1 carcinogen and a major causative agent of gastrointestinal ulcers, gastric adenocarcinoma, and gastric lymphoma. While antibiotics and proton pump inhibitors are effective treatments, they are associated with risks of reinfection, patient dissatisfaction, and increasing antibiotic resistance. Due to the bacterium's extremophile nature, designing potent drugs remains challenging. Therefore, an effective vaccine represents the most suitable prophylactic option for mass administration. - Source: PubMed
Publication date: 2026/03/18
Gollapalli PavanGnanasekaran Tamizh Selvan - Reprogramming tumor-associated macrophages (TAMs) from the pro-tumoral M2-like state to the immunostimulatory M1-like phenotype has emerged as a promising strategy for tumor therapy. However, most M2-like TAMs are preferentially located in hypoxic regions of the tumor, which are poorly accessible to many advanced drug delivery systems, posing a significant challenge to effective TAM reprogramming. Here, leveraging the tropism of facultative anaerobic bacteria to localize and propagate in the hypoxic tumor, an optogenetically engineered Escherichia coli Nissle 1917 strain conjugated with murine STING agonist (EcN@UPD) was developed for cancer-specific immunotherapy. Upon near-infrared light illumination, the blue and UV emissions from upconversion nanoparticles (UCNPs) simultaneously activate the expression of Toll-like receptor (TLR) agonist, flaB, from EcN, and the release of photocaged murine STING agonist, DMXAA, respectively. This spatiotemporally synchronized dual release ensures co-localized STING and TLR5 agonists inside the hypoxic niche, repolarizing TAMs from the M2 to the M1 phenotype via synergistic TLR5-MAPK1-NF-κB and STING-NF-κB signaling. The polarization of TAMs enhances their antigen-presenting capacity and, more importantly, activates the cytotoxic, stem-like and memory CD8 T cells responses. This subsequently inhibits tumor growth, relapse, and metastasis in the murine 4T1 tumor model. Collectively, our work introduces the bacteria-based system that uses near-infrared light to dual-release immunotherapeutics for systemic anti-tumor immunity, opening new avenues for precise and effective cancer immunotherapy. - Source: PubMed
Publication date: 2026/04/02
Qiu YuzhiLiu YuntingChen SihanLiu YidiYu XiYang XiangliangZhang YanZhu Yanhong